ESMO-IO 22: Biomarker-Driven Therapeutics for NSCLC

2) I am Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert and now we are covering @myESMO #ESMOImmuno22 updates/review on “Biomarker Targeted therapies” in #LCSM! pic.twitter.com/43wAJCH3gR— pulmmed_ce (@Pulmmed_CE) January...

ESMO22: Updates on ADCs in Development for Lung Cancer

2) Now we are covering @myESMO #ESMO22 updates on #ADCs in development for #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD) from @IEOufficiale, Milan in Italy 🇮🇹 pic.twitter.com/GWgziWfkc7— pulmmed_ce (@Pulmmed_CE) November 2, 2022 3b) This...

ESMO22 Updates on HER2 Mutant Lung Cancer

2) In this program we are covering @myESMO #ESMO22 updates on #HER2 mutant #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD) from @IEOufficiale, Milan in Italy 🇮🇹 pic.twitter.com/8Rm1MxsPC7— pulmmed_ce (@Pulmmed_CE) October 26, 2022 3b) This...